[1]
Candelaria Hernández, M., López Karpovitch, X., Javier Mijangos, F., Montaño, E., Lemus Carmona, A., Guzmán Vázquez, S. and Soto Molina, H. 2017. Cost-Effectiveness of Azacitidine Compared with Low-Doses of Chemotherapy (LDC) in Myelodysplastic Syndrome (MDS). Global and Regional Health Technology Assessment. 4, 1 (May 2017), 114–121. DOI:https://doi.org/10.33393/grhta.2017.385.